FDMT

Company Overview — What Does 4D Molecular Therapeutics, Inc. Do?

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California. 4D Molecular Therapeutics, Inc. (FDMT) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David H. Kirn and employs approximately 120 people. With a market capitalization of $504M, FDMT is one of the notable companies in the Healthcare sector.

4D Molecular Therapeutics, Inc. (FDMT) Stock Rating — Reduce (April 2026)

As of April 2026, 4D Molecular Therapeutics, Inc. receives a Reduce rating with a composite score of 32.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.FDMT ranks #2,028 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, 4D Molecular Therapeutics, Inc. ranks #221 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FDMT Stock Price and 52-Week Range

4D Molecular Therapeutics, Inc. (FDMT) currently trades at $9.81. The stock lost $0.03 (0.3%) in the most recent trading session. The 52-week high for FDMT is $12.34, which means the stock is currently trading -20.5% from its annual peak. The 52-week low is $2.23, putting the stock 338.9% above its annual trough. Recent trading volume was 901K shares, suggesting relatively thin trading activity.

Is FDMT Overvalued or Undervalued? — Valuation Analysis

4D Molecular Therapeutics, Inc. (FDMT) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.03x, versus the sector average of 2.75x. The price-to-sales ratio is 4284.98x, compared to 1.66x for the average Healthcare stock.

At current multiples, 4D Molecular Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

4D Molecular Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

4D Molecular Therapeutics, Inc. (FDMT) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -40.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -35.9% versus the sector average of -33.1%.

The operating margin is -637940.9% (sector: -66.1%). Net profit margin stands at -557918.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1700.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FDMT Debt, Balance Sheet, and Financial Health

4D Molecular Therapeutics, Inc. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.39x, indicating strong short-term liquidity. Total debt on the balance sheet is $17M. Cash and equivalents stand at $49M.

FDMT has a beta of 1.33, meaning it is more volatile than the broader market — a $10,000 investment in FDMT would be expected to move 33.2% more than the S&P 500 on any given day. The stability factor score for 4D Molecular Therapeutics, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

4D Molecular Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, 4D Molecular Therapeutics, Inc. reported revenue of $122,000 and earnings per share (EPS) of $-2.42. Net income for the quarter was $-203M. Operating income came in at $-225M.

In FY 2025, 4D Molecular Therapeutics, Inc. reported revenue of $85M and earnings per share (EPS) of $-2.42. Net income for the quarter was $-140M. Revenue grew 230194.6% year-over-year compared to FY 2024. Operating income came in at $-160M.

In Q3 2025, 4D Molecular Therapeutics, Inc. reported revenue of $90,000 and earnings per share (EPS) of $-1.01. Net income for the quarter was $-57M. Revenue grew 2900.0% year-over-year compared to Q3 2024. Operating income came in at $-61M.

In Q2 2025, 4D Molecular Therapeutics, Inc. reported revenue of $15,000 and earnings per share (EPS) of $-0.98. Net income for the quarter was $-55M. Revenue grew 200.0% year-over-year compared to Q2 2024. Operating income came in at $-59M.

Over the past 8 quarters, 4D Molecular Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $5,000 to $122,000. Investors analyzing FDMT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FDMT Dividend Yield and Income Analysis

4D Molecular Therapeutics, Inc. (FDMT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FDMT Momentum and Technical Analysis Profile

4D Molecular Therapeutics, Inc. (FDMT) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

FDMT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, 4D Molecular Therapeutics, Inc. (FDMT) ranks #221 out of 838 stocks based on the Blank Capital composite score. This places FDMT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FDMT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FDMT vs S&P 500 (SPY) comparison to assess how 4D Molecular Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

FDMT Next Earnings Date

No upcoming earnings date has been announced for 4D Molecular Therapeutics, Inc. (FDMT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FDMT? — Investment Thesis Summary

The quantitative profile for 4D Molecular Therapeutics, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers. High volatility (stability score 29/100) increases portfolio risk.

In summary, 4D Molecular Therapeutics, Inc. (FDMT) earns a Reduce rating with a composite score of 32.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FDMT stock.

Related Resources for FDMT Investors

Explore more research and tools: FDMT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FDMT head-to-head with peers: FDMT vs AZN, FDMT vs SLGL, FDMT vs VMD.